News

Early Breast Cancer Chemotherapy: Long Term Findings

Richard Peto
Richard Peto

REFERENCE: Lancet 371:29-40; January 5, 2008
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He talks with Peter Goodwin following the group’s most recent publication in The Lancet.

Buy + Download Now This Interview

Download this interview

Similar Interviews

  • Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
  • Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
  • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

  • Audio Journal of Oncology 14.1, February 2006
  • Reporting from: - San Antonio Breast Cancer Symposium 2005 In this edition: The targeted drug trastuzumab may be used in place of anthracyclines

    Post a comment